An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia
Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, Franceschini G
Metabolism: clinical and experimental · 93 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2004-01-28 · Metabolism · vol. 53 · número 2 · págs. 153–158
- Editorial
- Elsevier BV
- Citado
- 132 citas · más que el 98% de estudios similares · 9.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 55 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Paraoxonase enzyme and polymorphisms · Lipoproteins and Cardiovascular Health
- Palabras clave
- omega-3 polyunsaturated fatty acids, Omacor, HDL2, HDL3 cholesterol, HDL subfractions, familial combined hyperlipidemia, eicosapentaenoic acid, docosahexaenoic acid, paraoxonase, HDL apolipoproteins, lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein, triglycerides, apolipoprotein B, cardiovascular risk
- MeSH
- humans, aryldialkylphosphatase, phosphatidylcholine-sterol o-acyltransferase, glycoproteins, fatty acids, omega-3, docosahexaenoic acids, triglycerides, apolipoproteins a, carrier proteins, ultracentrifugation, electrophoresis, polyacrylamide gel, cross-over studies, double-blind method, particle size, adult, female, male, cholesterol, ldl, hyperlipidemias, cholesterol, hdl, cholesterol ester transfer proteins
7 autores
- Laura Calabresi🇮🇹University of Milan
- Barbara Villa🇮🇹University of Milan
- Monica Canavesi🇮🇹University of Milan
- Cesare Riccardo Sirtori🇮🇹University of Milan
- Richard William James🇨🇭University Hospital of Geneva
- Franco Bernini🇮🇹University of Parma
- Guido Franceschini🇮🇹 · autor de correspondenciaUniversity of Milan
Resumen
El texto original del estudio, en el idioma en que se publicó.
A remarkable reduction of plasma concentrations of high-density lipoproteins (HDL), especially of the HDL(2) subfraction, is one of the typical lipoprotein alterations found in patients with familial combined hyperlipidemia (FCHL). Fourteen FCHL patients received 4 capsules daily of Omacor (an omega-3 polyunsaturated fatty acid [omega3 FA] concentrate providing 1.88 g of eicosapentaenoic acid [EPA] and 1.48 g of docosahexaenoic acid [DHA] per day; Pronova Biocare, Oslo, Norway) or placebo for 8 weeks in a randomized, double-blind, crossover study. Plasma triglycerides were 44% lower, and LDL cholesterol and apoliporpotein (apo)B were 25% and 7% higher after Omacor than placebo. HDL cholesterol was higher (+8%) after Omacor than placebo, but this difference did not achieve statistical significance. Omacor caused a selective increase of the more buoyant HDL(2) subfraction; plasma HDL(2) cholesterol and total mass increased by 40% and 26%, respectively, whereas HDL(3) cholesterol and total mass decreased by 4% and 6%. Both HDL(2) and HDL(3) were enriched in cholesteryl esters and depleted of triglycerides after Omacor. No changes were observed in the plasma concentration of major HDL apolipoproteins, LpA-I and LpA-I:A-II particles, lecithin:cholesterol acyltransferase (LCAT), and cholesteryl ester transfer protein (CETP). The plasma concentration of the HDL-bound antioxidant enzyme paraoxonase increased by 10% after Omacor. Omacor may be helpful in correcting multiple lipoprotein abnormalities and reducing cardiovascular risk in FCHL patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.